IPHA (Innate Pharma) Long-Term Debt: $16.01 Mil (As of Dec. 2025)


IPHA Innate Pharma SA IPHA
41 GF Score
Price $1.80
GF Value $0.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Long-Term Debt?

Innate Pharma IPHA -2.44% 41 Long-Term Debt is $16.01 Mil as of Dec. 2025. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Innate Pharma's Long-Term Debt for the quarter that ended in Dec. 2025 was $16.01 Mil.

Innate Pharma's quarterly Long-Term Debt declined from Dec. 2024 ($23.23 Mil) to Jun. 2025 ($20.69 Mil) and declined from Jun. 2025 ($20.69 Mil) to Dec. 2025 ($16.01 Mil).

Innate Pharma's annual Long-Term Debt declined from Dec. 2023 ($33.38 Mil) to Dec. 2024 ($23.23 Mil) and declined from Dec. 2024 ($23.23 Mil) to Dec. 2025 ($16.01 Mil).

Innate Pharma  (NAS:IPHA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Innate Pharma Long-Term Debt Related Terms

Innate Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Innate Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma Long-Term Debt Chart

Innate Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.98 41.24 33.38 23.23 16.01

Innate Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.38 0.00 23.23 20.69 16.01
IPHA
41GF Score
Innate Pharma SA IPHA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $16.01 Mil mean?
Innate Pharma (IPHA) has a Long-Term Debt of $16.01 Mil as of Dec. 2025.
Is Innate Pharma's Long-Term Debt too high?
Innate Pharma's current Long-Term Debt is $16.01 Mil. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Long-Term Debt compare to VRTX and REGN?
Innate Pharma's Long-Term Debt of $16.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Innate Pharma's current Long-Term Debt is $16.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $1.80 — trading 1100% above its estimated fair value. The current Long-Term Debt is $16.01 Mil. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Long-Term Debt is $16.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innate Pharma (IPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.80 is trading 1100% above its estimated GF Value™ of $0.15. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHA:

  • Long-Term Debt: $16.01 Mil
  • GF Value™: $0.15 vs. price of $1.80 (1100% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score

Get the complete analysis for IPHA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.15
GF Value